Calidi Biotherapeutics, Inc. SEC filings CLDI

Calidi Biotherapeutics, Inc. has 406 filings in SEC EDGAR's recent list, going back to May 17, 2021. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 25, 2026 (listing notice, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Jun 5, 2026 —
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Apr 29, 2026 Apr 29, 2026
PRE 14A Preliminary proxy statement Apr 17, 2026 Apr 17, 2026
DEFA14A Additional proxy material May 23, 2025 —
DEF 14A Proxy statement May 23, 2025 May 23, 2025
PRE 14A Preliminary proxy statement May 12, 2025 May 12, 2025
DEF 14A Proxy statement Aug 20, 2024 Aug 19, 2024
DEF 14A Proxy statement May 9, 2024 May 9, 2024
PRE 14A Preliminary proxy statement Apr 29, 2024 Apr 29, 2024
DEF 14A Proxy statement Aug 23, 2022 Sep 9, 2022
PRE 14A Preliminary proxy statement Aug 8, 2022 Aug 8, 2022

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CLDI (NYSE), CLDWW (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
1855485
Former names
Calidi Biotherapeutics, Inc. (until Sep 25, 2026); First Light Acquisition Group, Inc. (until Sep 19, 2023)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.